INSUBCONTINENT EXCLUSIVE:
NEW DELHI: A professional panel of the main drug regulative authority has actually recommended market authorisation for Serum Institute of
Indias Covid vaccine, Covovax, as a heterologous booster dosage for grownups who have actually been administered two doses of Covishield or
Covaxin.SII director (government - & regulatory affairs) Prakash Kumar Singh had just recently written a letter to DCGI for approval of
Covovax booster dosage for those aged 18 and above in view of escalating Covid scenario in some countries, sources said
The subject expert committee (SEC) of the Central Drug Standards Control Organisation (CDSCO) on Wednesday deliberated on the concern and
suggested for market authorisation of Covid jab Covovax as a heterologous booster dose for grownups who have actually been administered two
doses of Covishield or Covaxin, said an official.The DCGI had actually approved Covovax for restricted usage in emergency situation
scenarios in grownups on December 28, 2021, in the 12-17 age on March 9, 2022 and likewise in kids aged 7-11 years on June 28, 2022 based on
Covovax is manufactured through innovation transfer from Novavax
It was approved emergency-use listing by the WHO on December 17, 2021.
